


# Results of the BRIDGE trial reported at TCT 2011

November 9 2011



The first stage of BRIDGE identified the cangrelor dose that maintains a "thienopyridine-like" level of platelet inhibition. The second stage reported today was a prospective, randomized, double-blind, placebo-controlled trial in 210 patients with an acute coronary syndromes (ACS) or treated with a coronary stent (bare metal stent or drug eluting stent) on a thienopyridine awaiting coronary artery bypass grafting (CABG). After thienopyridine discontinuation (

Citation: Results of the BRIDGE trial reported at TCT 2011 (2011, November 9) retrieved 4 May 2024 from <https://medicalxpress.com/news/2011-11-results-bridge-trial-tct.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.